Outsourcing is presently considered the preferred business model for the development of companion diagnostic tests for personalized therapeutic interventions
Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market, 2020 – 2030” report to its list of offerings.
It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).